← Back to guidelines
Allergy & Immunology254 papers

2-methyl-3-hydroxybutyric aciduria

Last edited: 4/15/2026

Overview

2-methyl-3-hydroxybutyric aciduria is a rare metabolic disorder characterized by elevated levels of 3-methylglutaconic acid in urine, often associated with neurological abnormalities and developmental delay. It can be linked to mutations in the OPA3 gene, though not all cases present with classic Costeff syndrome features. 1

Diagnosis

  • Key Diagnostic Criteria: Elevated levels of 3-methylglutaconic acid in urine.
  • Recommended Tests: Urine organic acid analysis to detect elevated 3-methylglutaconic acid.
  • Genetic Testing: Screening for OPA3 gene mutations, particularly for variations like c.231T>C, though clinical significance may vary. 1
  • Management

  • First-Line Treatments: Currently, no specific pharmacological treatments are widely recommended; management focuses on supportive care.
  • Adjunctive Therapies: Multidisciplinary approach including physical therapy, occupational therapy, and educational support tailored to neurological and developmental needs.
  • Dietary Considerations: Specific dietary modifications are not universally prescribed but may be considered based on individual metabolic profiles.
  • Special Populations

  • Pediatrics: Early intervention with developmental support is crucial for improving outcomes. 1
  • Comorbidities: Management should address coexisting neurological symptoms and developmental delays comprehensively. 1
  • Key Recommendations

  • Perform urine organic acid analysis for suspected cases to confirm elevated 3-methylglutaconic acid levels. (Evidence: Moderate 1)
  • Consider genetic testing for OPA3 mutations, particularly focusing on clinically significant variants beyond c.231T>C. (Evidence: Moderate 1)
  • Implement a multidisciplinary supportive care plan including physical, occupational, and educational therapies for affected individuals. (Evidence: Expert opinion)
  • References

    1 Neas K, Bennetts B, Carpenter K, White R, Kirk EP, Wilson M et al.. OPA3 mutation screening in patients with unexplained 3-methylglutaconic aciduria. Journal of inherited metabolic disease 2005. link 2 Schneider B, Müller R, Frank R, Lingens F. Site-directed mutagenesis of the 2-haloalkanoic acid dehalogenase I gene from Pseudomonas sp. strain CBS3 and its effect on catalytic activity. Biological chemistry Hoppe-Seyler 1993. link

    Original source

    1. [1]
      OPA3 mutation screening in patients with unexplained 3-methylglutaconic aciduria.Neas K, Bennetts B, Carpenter K, White R, Kirk EP, Wilson M et al. Journal of inherited metabolic disease (2005)
    2. [2]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG